» NATAP Does EASL 2012 AIDS Action Baltimore

EASL: Closing Summary by Jean-Michel Pawlotsky: New HCV Drug Development, Goodbye Interferon?, Triple, QUAD, IFN-Free, Adherence, New HCV Drugs – (04/26/12)

EASL: Closing Summary by Jean-Michel Pawlotsky Part 3: New data on telaprevir & boceprevir, post-transplant telaprevir/boceprevir treatment in patients with severe recurrence – (04/26/12)
EASL: Closing Summary by Jean-Michel Pawlotsky Part 2: New HCV Models – (04/26/12)
EASL: Closing Summary by Jean-Michel Pawlotsky Part 1 Genetics, HBV Clinical Guidelines, HBV, HCV Fibrosis Progression, HBC Nucleotides, Alisporivir for HBV – (04/26/12)

Subject: NATAP/EASL: High HCV Cure/SVR Rates/New HCV Drugs

HIGHLIGHTS

from Jules: here are highlights from the EASL HCV liver conference in Barcelona last week, there are sooo many highlights: # 1 – interferon-free therapy is here with cure/SVR rates of 88-100% in initial studies using only initial regimens, the regimens can only get better, and so they will as researchers & companies seek to make better drug regimen combinations with more potent combinations; for prior null responders although initial research sees they are harder to treat succussfully with all-oral new HCV drug regimens, future research will explore what potent combinations using more drugs with more potency is successful for this harder to treat group, but several studies here show that QUAD therapy certainly appears to be succesful for them with 2 orals + peg/rbv achieving 100% SVR rates in some studies.

EASL 47th Annual Meeting
Barcelona, Spain
April 18th – 22nd 2012

EASL: Interferon-Free Regimens at EASL – (04/24/12)

EASL: Potent Viral Suppression With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (Nucleotide NS5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With Chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2) – 100% SVR (04/19/12)

EASL: A 12-Week Interferon-Free Regimen of ABT-450/r + ABT-333 + Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naïve HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders – 92% SVR (04/23/12)

EASL: A 12-Week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naïve HCV IL28B-CC Genotype-1-Infected Subjects – 90% SVR (04/19/12)

EASL: Once Daily GS-7977 Plus Ribavirin in HCV Genotypes 1-3: The ELECTRON Trial -88% SVR (04/21/12)

EASL: GS-7977 + PEG/RBV in HCV Genotype 1: The ATOMIC Trial An End To Response-Guided Therapy – 97% SVR (04/20/12)

EASL: SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, +/- ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2 – 70% SVR (04/22/12)

EASL: Dual Oral Therapy with NS5A Inhibitor Daclatasvir (BMS-790052) and NS3 Protease Inhibitor Asunaprevir (BMS-650032) in HCV Genotype 1b-Infected Null Responders or Patients Ineligible/Intolerant to Peginterferon/Ribavirin – 77% SVR (04/19/12)

EASL: TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial – 51% SVR null responders; 75% prior partial responders; 85% prior relapsers (04/19/12)

EASL: RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNα-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 36 INTERIM ANALYSIS – Roche protease 90% SVR (04/22/12)

EASL: Confirmation That Quadruple Therapy With Daclatasvir (NS5A Inhibitor), Asunaprevir (NS3 Inhibitor) and Peginterferon/Ribavirin Results in a High Rate of SVR4 in HCV Genotype 1 Null Responders – (04/19/12)